Clinical characteristics and associated factors of pediatric acute disseminated encephalomyelitis patients with MOG antibodies: a retrospective study in Hangzhou, China

Table 3 Associations of clinical indicators with MOG-IgG-positive ADEM patients.

Factors	MOG-IgG-positive group n = 35	MOG-IgG-negative group n = 50	B	p value	OR	95% CI
Gender, male, n (%)	21 (60)	28 (56)	0.032	0.970	1.03	(0.193, 5.509)
Onset age, months, median (range)	69 (20–138)	76 (13–178)	−0.007	0.575	0.993	(0.970, 1.017)
Disease duration, days, median (range)	10 (1–30)*	6 (0.5–30)	0.168	0.008	1.183	(1.045, 1.339)
Meningeal involvement, n (%)	11 (31.4)*	4 (8)	4.445	0.001	85.158	(6.199, 1169.853)
Frontal lobe involvement, n (%)	29 (82.9)*	29 (58)	2.703	0.027	51.824	(2.867, 936.883)
Relapse, n (%)	5 (14.3)	1 (2)	2.978	0.106	19.639	(0.533, 723.340)
Serum TNF, (pg/ml), median (range)	1.7 (1–12.4)	2.2 (1–34)	−0.147	0.160	0.863	(0.703, 1.060)
Serum IFN-γ, (pg/ml), median (range)	1.3 (1–9.4)	3 (1–64)	−0.114	0.581	0.893	(0.596, 1.336)

ADEM acute disseminated encephalomyelitis, MOG myelin oligodendrocyte glycoprotein, MOG-IgG-positive ADEM patients with positive anti-MOG antibodies in serum, MOG-IgG-negative ADEM patients without positive anti-MOG antibodies in serum, TNF tumor necrosis factor, IFN-γ interferon γ OR odds ratio, 95% CI 95% confidence interval. Binary logistic regression was used for multivariate analyses.
*indicates MOG-IgG-positive group vs. MOG-IgG-negative group, p < 0.05.

ISSN: 1471-2377